Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of “Buy” by Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $34.50.

Several equities research analysts recently commented on the company. Maxim Group raised their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald raised their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Piper Sandler began coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CAPR. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics in the third quarter valued at approximately $133,000. Rhumbline Advisers bought a new position in shares of Capricor Therapeutics in the second quarter valued at approximately $147,000. The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics during the third quarter worth $161,000. Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the third quarter worth $192,000. Finally, BNP Paribas Financial Markets boosted its position in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,872 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $13.70 on Monday. The business has a 50 day simple moving average of $15.46 and a 200 day simple moving average of $11.60. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The stock has a market capitalization of $622.94 million, a P/E ratio of -12.92 and a beta of 4.08.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.